knowledge -WSS

knowledge

author：Wikipedia 2025-09-10 16:44:55 - browse：14

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

WSS

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Harvard's David Sinclair gets blowback over aging

How to keep neuroscience’s past racism from being its future

Keeping primary care docs in field isn't impossible, says AAFP CEO

Virtual care provider acquires bankrupt Pear's prescription apps

Three trends to watch in biotech in 2024

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Sports medicine is finally prioritizing gender equality

Fetal cell organoids grown from amniotic fluid, study finds

Hollywood unions extend contract negotiations for actors

Biden's 'march

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Longer MASH drug regimen improved liver, Akero study finds

Wildfire smoke exposes gaps in outdoor worker protections

Medicare drug price negotiation hasn't dried up venture capital

Trump demands the U.S. pay no more for drugs than other countries … again

Ancient Greek ideas underpin modern concepts of pregnancy

Wikipedia

Ozempic has benefits for kidney disease as well as diabetes

What STAT readers think about the FDA and patient advocacy

Christmas in the PICU brings some surprising joy

Microsoft's Peter Lee: Generative AI could help doctors be more human

A new approach to psychiatric drug development

Microsoft's Peter Lee: Generative AI could help doctors be more human

hotspot

hotspot

entertainment

leisure time